Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Mallinckrodt
Moodys
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RANEXA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ranexa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00832572 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Terminated Gilead Sciences Phase 4 2009-01-01 This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease. Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.
NCT00914316 Supervised Treadmill Exercise And Ranolazine For Intermittent Claudication Of Lower Extremities Completed William Beaumont Hospitals N/A 2009-05-01 The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. Investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. Lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication.
NCT01345188 Ranolazine in Ischemic Cardiomyopathy Completed Gilead Sciences Phase 4 2011-04-01 Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.
NCT01345188 Ranolazine in Ischemic Cardiomyopathy Completed Midwest Cardiovascular Research Foundation Phase 4 2011-04-01 Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.
NCT01435174 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed Gilead Sciences Phase 4 2011-10-01 End-stage renal disease (ESRD) patients often develop cardiovascular complications, and cardiovascular disease is the leading cause of death in this population. Ranolazine's ability to treat angina without reducing heart rate or blood pressure makes it an important option for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD patients on and off hemodialysis. Results of the proposed study will provide initial dosing estimates for a follow-up, multiple-dose pharmacokinetic study in this population.
NCT01435174 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed University of Michigan Phase 4 2011-10-01 End-stage renal disease (ESRD) patients often develop cardiovascular complications, and cardiovascular disease is the leading cause of death in this population. Ranolazine's ability to treat angina without reducing heart rate or blood pressure makes it an important option for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD patients on and off hemodialysis. Results of the proposed study will provide initial dosing estimates for a follow-up, multiple-dose pharmacokinetic study in this population.
NCT01505179 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction Enrolling by invitation Gilead Sciences N/A 2011-02-01 The purpose of this study is to determine whether treatment with Ranolazine will improve exercise capacity in patients with Heart Failure with preserved left ventricular ejection fraction.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ranexa

Condition Name

Condition Name for Ranexa
Intervention Trials
Cardiomyopathy 2
Coronary Artery Disease 2
Myotonia Congenita (Enrollment Complete) 1
Pulmonary Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ranexa
Intervention Trials
Cardiomyopathies 4
Ischemia 2
Myocardial Ischemia 2
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ranexa

Trials by Country

Trials by Country for Ranexa
Location Trials
United States 10
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ranexa
Location Trials
Michigan 2
Louisiana 2
Ohio 1
Massachusetts 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ranexa

Clinical Trial Phase

Clinical Trial Phase for Ranexa
Clinical Trial Phase Trials
Phase 4 5
Phase 2 2
N/A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ranexa
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Enrolling by invitation 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ranexa

Sponsor Name

Sponsor Name for Ranexa
Sponsor Trials
Gilead Sciences 8
Cardiovascular Institute of the South Clinical Research Corporation 1
IRCCS San Raffaele 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ranexa
Sponsor Trials
Other 10
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Colorcon
AstraZeneca
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.